Prosecution Insights
Last updated: October 02, 2026
Application No. 17/920,000

DRUG ANTIBODY CONJUGATES

Final Rejection §112
Filed
Oct 19, 2022
Priority
Apr 21, 2020 — EU 20382320.8 +1 more
Examiner
ROBINSON, MIKHAIL O'DONNEL
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pharma Mar S.A.
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
77 granted / 130 resolved
-0.8% vs TC avg
Strong +42% interview lift
Without
With
+42.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
48 currently pending
Career history
163
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
41.0%
+1.0% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
22.2%
-17.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 130 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Applicants’ response, dated 07/02/2026, is acknowledged. Claims 120, 127-128, 131 and 146 have been amended. Claim 155 has been added, no new matter was added. Claims 120-133, 136, 139, 145-146, 149, 152 and 155 are pending and are now evaluated on their merits. Priority This application claims foreign benefit to application EP20382320, dated 04/21/2020. Response to Arguments Applicant’s arguments, see Page 1, filed 07/02/2026, with respect to the 112b rejection of claims 120-126, 129-130, 132-133, 136, 139, 145-146 and 152 have been fully considered and are persuasive by the amendment to claim 120 to clarify the limitations of X, T and Ab. The rejection of claims 120-126, 129-130, 132-133, 136, 139, 145-146 and 152 has been withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 120-133, 136, 145-146, 149, 152 and 155 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 120, the phrase "Rx" renders the claim indefinite because it is unclear what the limitations are to Rx. The claim fails to recite the limitations of the substituent Rx. Ultimately the metes and bounds of the claim are unclear. Regarding claim 31, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claims 121-133, 136, 145-146, 149, 152 and 155 are rendered indefinite as depending from claim 120 thus carrying the limitation of Rx without further limiting. Allowable Subject Matter Claim 139 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MIKHAIL O'DONNEL ROBINSON whose telephone number is (571)270-0777. The examiner can normally be reached Monday-Friday 7:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MIKHAIL O'DONNEL. ROBINSON Examiner Art Unit 1627 /MIKHAIL O'DONNEL ROBINSON/Examiner, Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Oct 19, 2022
Application Filed
Jun 12, 2023
Response after Non-Final Action
Apr 02, 2026
Non-Final Rejection mailed — §112
Jul 02, 2026
Response Filed
Sep 22, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746257
IRON SUPPLEMENT COMPOSITIONS AND METHODS OF USE THEREOF
1y 7m to grant Granted Sep 29, 2026
Patent 12734173
USE OF NUCLEOTIDE SYNTHESIS INHIBITORS FOR TARGETED THERAPY IN MLL3/4 COMPASS MUTANT CANCER
3y 3m to grant Granted Sep 15, 2026
Patent 12728128
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
4y 10m to grant Granted Sep 08, 2026
Patent 12721850
LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF
2y 10m to grant Granted Sep 01, 2026
Patent 12709608
4-Amino Pyrimidine Compounds for the Treatment of Cancer
3y 9m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+42.1%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 130 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month